Program
trastuzumab deruxtecan
Also written as “Trastuzumab deruxtecan”, “Trastuzumab Deruxtecan” and “DS-8201a”.
Its studies are mostly in Breast Neoplasms · Carcinoma, Non-Small-Cell Lung · Stomach Neoplasms · Neoplasm Metastasis · Endometrial Neoplasms, led by 4 companies.
Drug pageTrastuzumab deruxtecan: every studyAll 120 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Daiichi Sankyoits history only | 2611 open or running | phase 3since Apr 13, 2018 | Sep 21, 2015 | Oct 1, 2027phase 3 · NCT05950945 |
| AstraZenecaits history only | 2120 open or running | phase 4since May 21, 2024 | Sep 22, 2017 | Feb 10, 2027phase 2 · NCT06271837 |
| Pfizerits history only | 10 open or running | phase 2since Aug 31, 2020 | Aug 31, 2020 | none ahead |
| Strata Oncologyits history only | 10 open or running | phase 2since Oct 1, 2021 | Oct 1, 2021 | none ahead |
Also a collaborator on its studies: Parexel, Merck, Bristol-Myers Squibb and Gilead Sciences.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 37 earlier studies, Sep 21, 2015 to Dec 8, 2023.
- Dec 9, 2016Named trastuzumab deruxtecanINNProposed as its International Nonproprietary Name in WHO's List 116
- Jan 19, 2024Phase 2 study in Breast NeoplasmsAstraZeneca · NCT06271837 · 127 enrolled · China
- May 21, 2024Phase 3 study in Biliary Tract NeoplasmsAstraZeneca · NCT06467357 · 620 planned · United States, Australia, Austria and more
- May 21, 2024Phase 4 study in Breast NeoplasmsAstraZeneca · NCT06429761 · 100 enrolled · India
- Dec 9, 2024Phase 3 study in Stomach NeoplasmsDaiichi Sankyo · NCT06731478 · 726 planned · United States, Argentina, Australia and more
- Dec 12, 2024Phase 3 study in HER2-positive Gastric CancerAstraZeneca · NCT06764875 · 840 planned · United States, Argentina, Australia and more
- Feb 5, 2025Phase 3 study in Ovarian NeoplasmsDaiichi Sankyo · NCT06819007 · 582 planned · United States, Australia, Austria and more
- Mar 11, 2025Phase 3 study in Endometrial NeoplasmsAstraZeneca · NCT06989112 · 600 planned · United States, Australia, Austria and more
- Mar 21, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungDaiichi Sankyo · NCT06899126 · 686 planned · United States, Argentina, Belgium and more
- Jun 3, 2025Phase 1 study in RecurrenceDaiichi Sankyo · NCT07015697 · 76 planned · United States, Brazil, France and more
- Jun 6, 2025Phase 3 study in Endometrial NeoplasmsDaiichi Sankyo · NCT07022483 · 710 planned · United States, Argentina, Chile and more
- Jun 24, 2025Phase 2 study in Stomach NeoplasmsAstraZeneca · NCT07069712 · 100 planned · United States, Canada, China and more
- Jun 25, 2026Phase 3 study in Breast NeoplasmsDaiichi Sankyo · NCT07683754 · 200 planned · United States
- Oct 22, 2026Primary completion moved from 2026-11-11 to 2027-05-03Date moved laterphase 3 · +6 months · NCT04784715
- Oct 26, 2026Primary completion moved from 2026-08-03 to 2028-02-17Date moved laterphase 3 · +18 months · NCT06174987
Ahead
- Feb 10, 2027Primary completion: phase 2 study in Breast NeoplasmsAstraZeneca · NCT06271837
- Mar 23, 2027Primary completion: phase 2 study in Pancreatic NeoplasmsAstraZeneca · NCT04482309
- May 3, 2027Primary completion: phase 3 study in Breast NeoplasmsAstraZeneca · NCT04784715
- May 4, 2027Primary completion: phase 2 study in Stomach NeoplasmsAstraZeneca · NCT04379596
TargetBeta
“An antibody-drug conjugate (ADC) composed of trastuzumab, a monoclonal antibody targeting human epidermal growth factor receptor 2 (ERBB2; EGFR2; HER2) ”NCIt, by rule
“Receptor protein-tyrosine kinase erbB-2 binding agent”ChEMBL 37, by rule
Other programs on ERBB2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Trastuzumabrule | Hoffmann-La Roche | phase 4 | 85 |
| pertuzumabrule | Hoffmann-La Roche | phase 4 | 56 |
| tucatinibrule | Pfizer | phase 4 | 25 |
| disitamab vedotin | RemeGen | phase 3 | 36 |
| trastuzumab rezetecanrule | Jiangsu HengRui Medicine | phase 3 | 36 |
| Lutetium-177 | Novartis | phase 3 | 24 |
| trastuzumab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 21 |
| Gallium-68 | Philogen | phase 3 | 17 |
| zongertinibrule | Boehringer Ingelheim | phase 3 | 15 |
| Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102 | Sino Biopharmaceutical | phase 3 | 13 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
| anbenitamab | CSPC Pharmaceutical Group | phase 3 | 12 |
Studies
All 49 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07683754Breast Neoplasms · United States | 3 | Recruiting | Daiichi Sankyo | Jul 4, 2030 | 200 |
| NCT07069712Stomach Neoplasms · United States, Canada, China and more | 2 | Recruiting | AstraZeneca | Nov 9, 2027 | 100 |
| NCT07022483Endometrial Neoplasms · United States, Argentina, Chile and more | 3 | Recruiting | Daiichi Sankyo | Feb 26, 2030 | 710 |
| NCT07015697Recurrence · United States, Brazil, France and more | 1 | Recruiting | Daiichi Sankyo | Dec 31, 2028 | 76 |
| NCT06899126Carcinoma, Non-Small-Cell Lung · United States, Argentina, Belgium and more | 3 | Recruiting | Daiichi Sankyo | Apr 24, 2030 | 686 |
| NCT06989112Endometrial Neoplasms · United States, Australia, Austria and more | 3 | Recruiting | AstraZeneca | Jan 19, 2029 | 600 |
| NCT06819007Ovarian Neoplasms · United States, Australia, Austria and more | 3 | Recruiting | Daiichi Sankyo | Nov 1, 2028 | 582 |
| NCT06764875HER2-positive Gastric Cancer · United States, Argentina, Australia and more | 3 | Recruiting | AstraZeneca | Apr 27, 2029 | 840 |
| NCT06731478Stomach Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | Daiichi Sankyo | Jun 1, 2028 | 726 |
| NCT06467357Biliary Tract Neoplasms · United States, Australia, Austria and more | 3 | Recruiting | AstraZeneca | Jun 12, 2028 | 620 |
| NCT06429761Breast Neoplasms · India | 4 | Active, not recruiting | AstraZeneca | Oct 31, 2026 | 100 |
| NCT06271837Breast Neoplasms · China | 2 | Active, not recruiting | AstraZeneca | Feb 10, 2027 | 127 |
| NCT06174987Neoplasm Metastasis · United States, Australia, Brazil and more | 3 | Recruiting | Daiichi Sankyo | Feb 17, 2028 | 75 |
| NCT05950945Breast Neoplasms · United States, Australia, Belgium and more | 3 | Recruiting | Daiichi Sankyo | Oct 1, 2027 | 250 |
| NCT05246514HER2-mutant Non-Small Cell Lung Cancer · China | 2 | Active, not recruiting | AstraZeneca | Nov 4, 2024 | 72 |
| NCT05113251Breast Neoplasms · United States, Brazil, Bulgaria and more | 3 | Active, not recruiting | AstraZeneca | Mar 12, 2025 | 927 |
| NCT05097599Neoplasms · United States | 2 | Terminated | Strata Oncology | Jun 12, 2024 | 11 |
| NCT05048797Carcinoma, Non-Small-Cell Lung · United States, Austria, Belgium and more | 3 | Active, not recruiting | AstraZeneca | Jun 9, 2026 | 454 |
| NCT04989816Adenocarcinoma · China | 2 | Completed | AstraZeneca | Jun 16, 2023 | 95 |
| NCT04784715Breast Neoplasms · United States, Argentina, Belgium and more | 3 | Active, not recruiting | AstraZeneca | May 3, 2027 | 1,157 |
| NCT04739761Breast Neoplasms · United States, Australia, Belgium and more | 3 | Active, not recruiting | AstraZeneca | Feb 8, 2024 | 506 |
| NCT04744831Colorectal Neoplasms · United States, Australia, Belgium and more | 2 | Completed | Daiichi Sankyo | Nov 1, 2022 | 122 |
| NCT04704934Stomach Neoplasms · Argentina, Belgium, Brazil and more | 3 | Active, not recruiting | Daiichi Sankyo | Aug 31, 2026 | 490 |
| NCT04686305Carcinoma, Non-Small-Cell Lung · United States, Australia, Belgium and more | 1 | Recruiting | AstraZeneca | Jun 30, 2027 | 304 |
| NCT04644237Carcinoma, Non-Small-Cell Lung · United States, Australia, Canada and more | 2 | Completed | Daiichi Sankyo | Dec 23, 2022 | 152 |
| NCT04622319HER2-Positive Primary Breast Cancer · United States, Argentina, Australia and more | 3 | Active, not recruiting | Daiichi Sankyo | Jul 2, 2025 | 1,600 |
| NCT04639219Neoplasm Metastasis · United States, Belgium, Canada and more | 2 | Active, not recruiting | AstraZeneca | Jan 25, 2023 | 102 |
| NCT04556773Breast Neoplasms · United States, Australia, Belgium and more | 1 | Active, not recruiting | AstraZeneca | Aug 16, 2023 | 138 |
| NCT04539938Breast Neoplasms · United States | 2 | Completed | Pfizer | Jul 15, 2024 | 70 |
| NCT04538742Breast Neoplasms · United States, Australia, Brazil and more | 2 | Active, not recruiting | AstraZeneca | Jan 31, 2025 | 245 |
| NCT04494425Breast Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | AstraZeneca | Mar 18, 2024 | 866 |
| NCT04482309Pancreatic Neoplasms · United States, Australia, Belgium and more | 2 | Active, not recruiting | AstraZeneca | Mar 23, 2027 | 477 |
| NCT04379596Stomach Neoplasms · United States, Brazil, Canada and more | 2 | Active, not recruiting | AstraZeneca | May 4, 2027 | 452 |
| NCT04042701Breast Neoplasms · United States, France, Spain and more | 1 | Active, not recruiting | Daiichi Sankyo | Jul 21, 2025 | 115 |
| NCT04014075Neoplasm Metastasis · United States, Belgium, Italy and more | 2 | Completed | Daiichi Sankyo | Nov 8, 2021 | 79 |
| NCT03734029Breast Neoplasms · United States, Austria, Belgium and more | 3 | Completed | Daiichi Sankyo | Jan 11, 2022 | 557 |
| NCT03742102Triple Negative Breast Neoplasms · United States, Canada, Poland and more | 2 | Active, not recruiting | AstraZeneca | Nov 29, 2024 | 243 |
| NCT03523572Breast Neoplasms · United States, Belgium, France and more | 1 | Completed | Daiichi Sankyo | Jul 22, 2021 | 86 |
| NCT03529110Breast Neoplasms · United States, Australia, Belgium and more | 3 | Completed | Daiichi Sankyo | May 21, 2021 | 524 |
| NCT03523585Breast Neoplasms · United States, Australia, Belgium and more | 3 | Completed | Daiichi Sankyo | Jun 30, 2022 | 608 |
| NCT03505710Carcinoma, Non-Small-Cell Lung · United States, France, Japan and more | 2 | Terminated | Daiichi Sankyo | May 3, 2021 | 181 |
| NCT03384940Colorectal Neoplasms · United States, Italy, Japan and more | 2 | Completed | Daiichi Sankyo | Aug 9, 2019 | 86 |
| NCT03383692Neoplasm Metastasis · Japan, Korea, Republic of, Taiwan | 1 | Completed | Daiichi Sankyo | Sep 26, 2018 | 40 |
| NCT03368196Adenocarcinoma · Taiwan | 1 | Completed | Daiichi Sankyo | Sep 14, 2018 | 12 |
| NCT03366428Breast Neoplasms · Japan | 1 | Completed | Daiichi Sankyo | Dec 5, 2018 | 51 |
| NCT03329690Gastrointestinal Neoplasms · Japan, Korea, Republic of | 2 | Completed | Daiichi Sankyo | Nov 8, 2019 | 233 |
| NCT03334617Carcinoma, Non-Small-Cell Lung · United States, Austria, Canada and more | 2 | Active, not recruiting | AstraZeneca | Sep 13, 2024 | 528 |
| NCT03248492Breast Neoplasms · United States, Belgium, Canada and more | 2 | Terminated | Daiichi Sankyo | Mar 21, 2019 | 253 |
| NCT02564900Neoplasms · United States, Japan | 1 | Completed | Daiichi Sankyo | Feb 1, 2019 | 292 |
How it is read
Names in the registry
- “Trastuzumab deruxtecan”, 22 entries
- “Trastuzumab Deruxtecan”, 10 entries
- “DS-8201a”, 7 entries
- “Trastuzumab deruxtecan (DS-8201a)”, 3 entries
- “T-DXd”, 2 entries
Conditions, from the studies’ own filings
- Breast Neoplasms, 19 studies
- Carcinoma, Non-Small-Cell Lung, 7 studies
- Stomach Neoplasms, 5 studies
- Neoplasm Metastasis, 4 studies
- Endometrial Neoplasms, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.